The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 01, 2011
Filed:
Jun. 03, 2009
Clare J Watkins, Abingdon, GB;
Maria Rosario Romero-martin, Didcot, GB;
Kathryn G Moore, Abingdon, GB;
James Ritchie, Abingdon, GB;
Paul W Finn, Abingdon, GB;
Ivars Kalvinsh, Riga, LV;
Einars Loza, Riga, LV;
Igor Starchenkov, Riga, LV;
Klara Dikovska, Riga, LV;
Rasma M Bokaldere, Riga, LV;
Vija Gailite, Riga, LV;
Maxim Vorona, Riga, LV;
Victor Andrianov, Riga, LV;
Daina Lolya, Riga, LV;
Valentina Semenikhina, Riga, LV;
Andris Amolins, Riga, LV;
C. John Harris, Sittingbourne, GB;
James E S Duffy, Sittingbourne, GB;
Clare J Watkins, Abingdon, GB;
Maria Rosario Romero-Martin, Didcot, GB;
Kathryn G Moore, Abingdon, GB;
James Ritchie, Abingdon, GB;
Paul W Finn, Abingdon, GB;
Ivars Kalvinsh, Riga, LV;
Einars Loza, Riga, LV;
Igor Starchenkov, Riga, LV;
Klara Dikovska, Riga, LV;
Rasma M Bokaldere, Riga, LV;
Vija Gailite, Riga, LV;
Maxim Vorona, Riga, LV;
Victor Andrianov, Riga, LV;
Daina Lolya, Riga, LV;
Valentina Semenikhina, Riga, LV;
Andris Amolins, Riga, LV;
C. John Harris, Sittingbourne, GB;
James E S Duffy, Sittingbourne, GB;
Topotarget UK Limited, Oxford, GB;
Abstract
This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the formula (1) wherein: A is an aryl group; Qis an aryl leader group having a backbone of at least 2 carbon atoms; J is an amide linkage selected from: —NRC(═O)— and —C(═O)NR—; Ris an amido substituent; and, Qis an acid leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psorias.